Abstract Body

Type 1 interferons (IFN-I) are potent innate antiviral effectors. However, harnessing these cytokines for HIV-1 prevention, treatment, and cure strategies has been hampered by an incomplete understanding of the role of endogenously produced IFN-I in viral control. To examine the kinetics of the IFN-I response over the course of HIV-1 infection, we generated 500 clonally-derived HIV-1 isolates from the plasma and CD4+ T cells of 26 individuals sampled prospectively before and after antiretroviral therapy (ART), and/or during analytical treatment interruption (ATI). Determining the concentration of IFN?2 and IFN? that reduced viral replication in vitro by 50% (IC50), we found consistent changes in the sensitivity of HIV-1 to IFN-I inhibition both across individuals and over time. IFN-I resistance was uniformly high during acute infection, decreased in all individuals in the first year post-infection, was reacquired concomitant with CD4+ T cell loss, and remained elevated in individuals with accelerated disease. Isolates obtained by viral outgrowth during suppressive ART were relatively IFN-I sensitive, resembling viruses circulating just prior to ART initiation. However, viruses that rebounded following treatment interruption displayed the highest degree of IFN?2 and IFN? resistance observed at any time during the infection course. Interestingly, IFN?2 IC50 values of rebound isolates from individuals treated with pegylated IFN?2 before and during ART interruption were on average 1.8-fold higher than those of rebound isolates from IFN?2 untreated individuals, and such differences were not observed for the corresponding IFN? IC50 values. IFN-I-resistant viruses did not share a particular biological phenotype, but some rebound viruses were exquisitely macrophage tropic. Finally, an analysis of post-ATI isolates generated by viral outgrowth suggested that treatment interruption may have re-seeded the reservoir with IFN-I resistant viruses in some patients. These findings indicate a dynamic interplay between host innate immune responses and the evolving HIV-1 quasispecies, with the relative contribution of IFN-I to HIV-1 control impacted by both ART and analytical treatment interruption. Although elevated at transmission, host innate pressures are the highest during viral rebound, limiting the viruses that successfully reactivate from latency to those that are IFN-I resistant.